Cardiovascular safety of phosphodiesterase inhibitors for treating erectile dysfunction in elderly men
Sign Up to like & getrecommendations! Published in 2017 at "Cochrane Database of Systematic Reviews"
DOI: 10.1002/14651858.cd011178.pub2
Abstract: Reason for withdrawal from publication This protocol has been withdrawn as the author team is unable to progress to the final review stage. This title is not open to a new author team as it… read more here.
Keywords: treating erectile; inhibitors treating; erectile dysfunction; cardiovascular safety ... See more keywords
Cardiovascular Safety of Denosumab Across Multiple Indications: A Systematic Review and Meta‐Analysis of Randomized Trials
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Bone and Mineral Research"
DOI: 10.1002/jbmr.4157
Abstract: The cardiovascular safety of denosumab has not yet been evaluated in a systematic review. This systematic review and meta‐analysis sought to quantify the number of randomized controlled trials (RCTs) of denosumab (against comparators) reporting cardiovascular… read more here.
Keywords: analysis; systematic review; cardiovascular safety; versus ... See more keywords
Cardiovascular Safety of Antidiabetic Drugs in the Hospital Setting
Sign Up to like & getrecommendations! Published in 2017 at "Current Diabetes Reports"
DOI: 10.1007/s11892-017-0884-1
Abstract: Purpose of ReviewPatients with diabetes and/or stress hyperglycemia requires good glycemic control in the hospital setting, often requiring the use of glucose-lowering therapy. Standard-of-care dictates that non-insulin therapy be discontinued, with insulin therapy initiated using… read more here.
Keywords: antidiabetic drugs; safety; insulin therapy; cardiovascular safety ... See more keywords
Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs
Sign Up to like & getrecommendations! Published in 2020 at "Drugs"
DOI: 10.1007/s40265-020-01364-2
Abstract: The incidence of osteoporosis and cardiovascular disease increases with age, and there are potentially shared mechanistic associations between the two conditions. It is therefore highly relevant to understand the cardiovascular implications of osteoporosis medications. These… read more here.
Keywords: anti osteoporosis; assessment cardiovascular; safety anti; cardiovascular safety ... See more keywords
Cardiovascular Outcome Trials of Diabetes and Obesity Drugs: Implications for Conditional Approval and Early Phase Clinical Development
Sign Up to like & getrecommendations! Published in 2017 at "Pharmaceutical Medicine"
DOI: 10.1007/s40290-017-0209-3
Abstract: Over the past decade, clinical development and regulatory review of investigational drugs for diabetes and obesity have been guided by heightened standards for pre- and post-marketing assessment of cardiovascular safety. In high-risk patients with type… read more here.
Keywords: risk; diabetes obesity; clinical development; cardiovascular safety ... See more keywords
A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of diabetes and its complications"
DOI: 10.1016/j.jdiacomp.2017.08.005
Abstract: AIMS FDA-approved drug labels are an important source of information for clinicians who prescribe medications for treatment of diabetes. We reviewed drug labels to (1) understand the landscape of classes of medications approved for type… read more here.
Keywords: drug labels; safety; cardiovascular safety; fda approved ... See more keywords
Cardiovascular safety of liraglutide for the treatment of type 2 diabetes
Sign Up to like & getrecommendations! Published in 2017 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2017.1313225
Abstract: ABSTRACT Introduction: Liraglutide is a GLP-1 RA that is an option for treatment of T2DM. Typical of all new glucose-lowering agents, its CV safety profile is of great interest. Areas covered: This article outlines the… read more here.
Keywords: treatment; safety; liraglutide; cardiovascular safety ... See more keywords
Newer formulations of intravenous iron: a review of their chemistry and key safety aspects – hypersensitivity, hypophosphatemia, and cardiovascular safety
Sign Up to like & getrecommendations! Published in 2021 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2021.1912010
Abstract: ABSTRACT Introduction: The newest intravenous (IV) iron products show an improved safety profile over predecessors, allowing for the rapid administration of relatively high doses. Ferric derisomaltose (FDI; also known as iron isomaltoside), ferric carboxymaltose (FCM),… read more here.
Keywords: safety; chemistry; fcm; cardiovascular safety ... See more keywords
Cardiovascular safety of COVID-19 studies: vaccines in real-world a systematic review and meta-analysis.
Sign Up to like & getrecommendations! Published in 2022 at "Expert review of vaccines"
DOI: 10.1080/14760584.2023.2150169
Abstract: OBJECTIVES To evaluate the cardiovascular safety of COVID-19 vaccines in the real world. METHODS Studies reported on any COVID-19 vaccine-related cardiovascular events in the population aged ≥ 12 years between January 1, 2020 and June… read more here.
Keywords: vaccines real; meta analysis; safety covid; risk ... See more keywords
Have we really demonstrated the cardiovascular safety of anti‐hyperglycaemic drugs? Rethinking the concepts of macrovascular and microvascular disease in type 2 diabetes
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.1111/dom.13207
Abstract: A primary goal of the treatment of type 2 mellitus is the prevention of morbidity and mortality associated with cardiovascular disease; however, anti‐hyperglycaemic drugs have the capacity to cause deleterious effects on the circulation, a… read more here.
Keywords: hyperglycaemic drugs; microvascular disease; disease; cardiovascular safety ... See more keywords
Evaluating the Cardiovascular Safety of Nonsteroidal Anti-Inflammatory Drugs.
Sign Up to like & getrecommendations! Published in 2017 at "Circulation"
DOI: 10.1161/circulationaha.117.027288
Abstract: Some drugs used to treat noncardiovascular conditions may adversely impact the cardiovascular status of individuals both with and without known cardiovascular disease. When the US Food and Drug Administration judges the potential cardiovascular safety signal… read more here.
Keywords: evaluating cardiovascular; phase; safety nonsteroidal; safety ... See more keywords